

Market Data

Nutriband Inc.
Nasdaq: NTRB

Industry	Pharma
Fiscal Year	Jan. 31
Price ¹	\$3.65
52 Week Range ¹	\$1.53-\$5.92
Market Cap ¹	\$40.0M
Shares Out.	11.0M
Float	3.7M
Avg. Vol (90-day)	34,607
Cash (mrq) ²	\$0.5M
LT Debt (mrq)	\$0.0M
Revenue (ttm)	\$2.1M

¹ As of May 2, 2024

² does not include proceeds from \$8.4M private placement in April 2024

Auditor:

Sadler, Gibb & Associates, LLC

Legal Counsel:

Michael Paige Law PLLC

Transfer Agent:

Equiniti Trust Company

nutriband.com

Company Overview

Nutriband is a pioneering US-based pharmaceutical company focused on the development and commercialization of transdermal technologies that improve the safety, comfort, and efficacy of FDA-approved drugs, benefitting patients, physicians, and payers. Nutriband's lead product technology, AVERSA™, is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, such as opioids, a \$22.8 billion global market.

The Company's first application for AVERSA™ is an abuse-deterrent fentanyl transdermal patch which it is being developed to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid-based pain treatments safe for all who need them. AVERSA™ technology has received patent protection in the US, EU, Australia, Japan, Mexico, and Russia, with patent protection pending in Canada. With anticipated peak annual sales of up to \$200 million upon FDA approval, and a strategic partnership with Kindeva for commercial development, Nutriband stands poised for significant growth. Nutriband's diversified structure, including revenue-generating subsidiaries and in-house manufacturing capabilities, solidifies its position as a unique player in the biopharma sector, promising investors a blend of innovation, sustainability, and market potential.

Nutriband Inc.



Investment Highlights


- Revolutionary AVERSA™ abuse-deterrent transdermal technology mitigates the risk of drug abuse, diversion, and accidental exposure
- Targeting opioid crisis with AVERSA™ Fentanyl – addressing a global market valued at \$22.8 billion
- AVERSA™ Fentanyl anticipated to reach peak annual sales of \$80 million to \$200 million upon FDA approval
- Streamlined 505(b)(2) NDA regulatory pathway requires only a single Phase 1 trial, significantly reducing the time and cost of development
- AVERSA™ Fentanyl is eligible for an expedited six-month FDA review
- Strong IP with patent protection in major markets including the US, EU, Australia, Japan, Mexico, and Russia, with pending patents in Canada
- Diversified business model includes revenue-generating subsidiaries that support the company's financial sustainability and reduce its reliance on external funding for research and development activities

Value Proposition

Nutriband presents a compelling opportunity, standing at the forefront of addressing the global opioid crisis with its revolutionary AVERSA™ abuse-deterrent transdermal technology. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of \$80 million to \$200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway for AVERSA™ Fentanyl, requiring only a single Phase 1 trial with the potential for an expedited six-month FDA review further accelerates the path to market.

Nutriband's robust IP portfolio, with patents secured in major markets worldwide and additional patents pending, safeguards its innovations, ensuring long-term competitiveness and market exclusivity. The company's diversified business model, bolstered by revenue-generating subsidiaries, provides a strong foundation and minimizes reliance on external funding for R&D.

Nutriband embodies a unique convergence of innovation, significant societal value, and strong growth prospects. With a streamlined path to market, clear vision, established strategic partnerships, and commitment to addressing one of healthcare's most pressing challenges, Nutriband is well-positioned for success.



Leadership Team



Gareth Sheridan
Founder and CEO
Nutriband



Serguei Melnik
Founder and President
Nutriband



Dr. Alan Smith
President 4P Therapeutics
FDA Expert Committee on
Complex Generics



Dr. Jeff Patrick
CSO Nutriband



Gerald Goodman
CFO Nutriband



Paddy Ryan
CTO Nutriband



Michael Myer
President Pocono
Pharmaceutical



Tyler Overk
Head of Active Intelligence



Dianna Mather
VP Finance